Lung Cancer Research Review, Issue 34

In this issue:

Ipilimumab + nivolumab in recurrent MPM
Transformation of EGFR-mutant NSCLC to SCLC
Nivolumab + low-dose ipilimumab in advanced/metastatic NSCLC
Maintenance defactinib contraindicated in advanced MPM
Nivolumab: an exposure–response relationship in NSCLC?
Afatinib in metastatic or recurrent HER2-mutant lung cancers
Combining PCB with checkpoint inhibition in NSCLC
FLAURA trial post-progression outcomes
Third-line nivolumab monotherapy in recurrent SCLC

Please login below to download this issue (PDF)